^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) + dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
Excerpt:
To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma....Among patients with BRAF mutations, objective responses were similar between selumetinib and temozolomide groups (11.1% and 10.7%, respectively). However, five of the six selumetinib partial responders were BRAF mutated.
DOI:
10.1158/1078-0432.CCR-11-1491
Source:
Title:
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
Excerpt:
We used 49 BRAF-mutant melanoma cell lines isolated from surgical specimens of patients not previously treated with BRAFV600E inhibitors….In addition, the AZD6244-BEZ235 combination induced a significantly stronger synergistic effect (lower CI values) against the whole panel of 49 melanoma cell lines compared to PLX4720-BEZ235...
DOI:
10.18632/oncotarget.6600
